Echoiq Limited · ASX:EIQ
Echoiq — Investor Presentation (February 2022)
20 slides from Echoiq's investor presentation, Feb 4, 2022
Slide 1: Echo IQ Corporate Presentation
Echo IQ CORPORATE PRESENTATION ISSUED FEBRUARY 2022
Slide 2: Disclaimer & Forward Looking Statements
Disclaimer & Forward Looking Statements This presentation has been prepared by ECHOIQ Limited (Echo IQ / ASX:EIQ). This document contains background information about Echo IQ current at the date of this presentation, 4 February 2022. The presentation is in summary form and does not purport to be all
Slide 3: Reinventing cardiac diagnostics using the power of artificial intelligence
Echo IQ Reinventing cardiac diagnostics using the power of artificial intelligence CORPORATE PRESENTATION | ISSUED FEBRUARY 2022
Slide 4: Echo IQ Corporate Snapshot
Echo IQ Corporate Snapshot SHARE PRICE 3 FEB, 2022 $0.145 ASX:EIQ SHARES ON ISSUE 394,332,713 OPTIONS ISSUED 197,425,713* MARKET CAPITALISATION c.A$57M NET CASH BALANCE (Dec 2021) A$2.519M (+ up to A$1.46M in 3/4/5 cent options due by end June 2022) TOP 10 Shareholders - c.39% of Company *Substantia
Slide 5: Investment Highlights
Investment Highlights Echo IQ has developed novel technology and proprietary algorithms designed to transform diagnosis of structural heart diseases, starting with the leading form of valvular heart disease - aortic stenosis Exclusive commercial access to NEDA (the world's largest and leading databa
Slide 6: What's the problem?
What's the problem? More people die from cardiovascular disease every year than any other cause. It claims the lives of 18 million people annually. Whilst treatment options have never been better, mis-diagnosis and under-diagnosis remain common. In Australia, for example, it is estimated that half o
Slide 7: How Does Echo IQ help?
How Does Echo IQ help? Echo IQ uses its AI-driven technology to enhance the diagnosis of structural heart disease. The company's algorithms, developed using advanced data science and machine learning, utilise world-leading cardiac big data. Our mission is to help reduce the number of patients curren
Slide 8: Access to world-leading cardiac Big Data
Access to world-leading cardiac Big Data Lack of access to large and highly relevant medical datasets has been a significant obstacle to transformational AI innovation in healthcare. 1.8M Patients' However. Records Echo IQ has a 17 year (7+10) agreement with the National Echo Database of Australia (
Slide 9: How BigData and AI can make healthcare MORE human
How BigData and AI can make healthcare MORE human In DEEP MEDICINE, leading physician Eric Topol reveals how artificial intelligence can help make healthcare human again. He explains how AI has the potential to transform everything doctors do, from note-taking and medical scans to diagnosis and trea
Slide 10: Introducing Echo IQ Enhanced Screening Program (ESP)
#impactinvesting #aiforgood Introducing Echo IQ Enhanced Screening Program (ESP) A proprietary AI-backed system that identifies patients at risk of mortality from structural heart disease. Assistive technology that also gives cardiologists extra time to care for their patients. A support tool for ca
Slide 11: Commercial Roadmap - Initial focus on US
Commercial Roadmap - Initial focus on US More than 20M The US has more TAVR replacements Echocardiograms are practicing and associated performed, at an average cardiologists than any hospitalisation cost of US$2500, in the other country estimated at more than US annually $3.5bn per year 20M 31,050 $
Slide 12: Revenue Sources: Echo IQ ESP
Revenue Sources: Echo IQ ESP Solution Regulatory Settings Timeframe Integration 1 2 3 Potentially Excluded RETROSPECTIVE Software from FDA oversight H2 2022 - H1 2023 & Reporting or subject to 510(k) ASSESSMENT Clearance* Potentially Excluded REAL-TIME PROFILING + Software from FDA oversight H1 2023
Slide 13: Retrospective Assessment Market Sizing
Retrospective Assessment Market Sizing Echocardiograms performed Retrospective Assessment would 20M in the US annually give clinics and hospitals the ability to apply another layer of analysis to echocardiographic measurement Three year "recent archive" data captured in the previous, week, 60M avail
Slide 14: Real-Time Profiling Market Sizing
Real-Time Profiling CORPORATE PRSENTATION | ISSUED FEBRUARY 2022 Market Sizing Real-Time Profiling would give Echocardiograms performed clinics and hospitals the ability to 20M in the US annually apply another layer of analysis to echocardiographic measurement data captured as echo's are performed.
Slide 15: How Patients benefit from AS
How Patients benefit from AS Patient Benefits Relevant Evidence Playford D, Bordin E, Mohamad R, et Our data indicates that c. 2,500 (2.5%) are al. currently receiving valve replacements. Enhanced Diagnosis of Severe Aortic Stenosis Using Artificial Intelligence: A For every However, our solution id
Slide 16: How HealthCare Sector benefits from AS
How HealthCare Sector benefits from AS Sector Impacts Relevant Evidence Reduction in emergency Validation Study on Risk Identification of AS presentations, with improved ability phenotype in 330,000 patients to plan treatment Per 100,000 Up to $137M in incremental Baker Insitute: White Paper Time to
Slide 17: Progress to commercialisation
Progress to commercialisation Retrospective observation and evaluation study Commenced Q4 2021 St Vincent's Sydney & Melbourne Expected conclusion Q2 2022 NEDA + Echo IQ + Extential Fully funded by Edwards LifeSciences* *NYSE:EW / Mkt. Cap. US$70B World's largest replacement aortic valve maker Comme
Slide 18: Who are we talking to?
Who are we talking to? Replacement Valve Echocardiography PACS & Reporting Cardiologists and Insurance Manufacturers Equipment Makers Software Suppliers Surgical Centres Providers Valve manufacturers Added value services that Enhancements that Systems that increase Early identification of risk, bene
Slide 19: Where to from here?
Where to from here? Receiving data from clinical study sites (St. Vincent's Sydney and Melbourne) with anticipated study conclusion approx. May 2022. Leveraging early interest from key players in the global valve, hardware and software sectors with plans for pilots, new test sites and commercial col
Slide 20: Echo IQ
Echo IQ Reinventing cardiac diagnostics using the power of artificial intelligence ASX: EIQ echoiq.ai CORPORATE PRESENTATION | ISSUED FEBRUARY 2022